These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16909001)

  • 1. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.
    Asami-Odaka A; Obayashi-Adachi Y; Matsumoto Y; Takahashi H; Fukumoto H; Horiguchi T; Suzuki N; Shoji M
    Neurodegener Dis; 2005; 2(1):36-43. PubMed ID: 16909001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology.
    Nemirovsky A; Shapiro J; Baron R; Kompaniets A; Monsonego A
    J Neuroimmunol; 2012 Jun; 247(1-2):95-9. PubMed ID: 22498096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active immunization trial in Abeta42-injected P301L tau transgenic mice.
    Kulic L; Kurosinski P; Chen F; Tracy J; Mohajeri MH; Li H; Nitsch RM; Götz J
    Neurobiol Dis; 2006 Apr; 22(1):50-6. PubMed ID: 16289870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunization of mice with an Abeta-Hsp70 vaccine.
    Koller MF; Mohajeri MH; Huber M; Wollmer MA; Roth Z'graggen BV; Sandmeier E; Moritz E; Tracy J; Nitsch RM; Christen P
    Neurodegener Dis; 2004; 1(1):20-8. PubMed ID: 16908970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
    Vasilevko V; Cribbs DH
    Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools.
    Mitani Y; Yarimizu J; Akashiba H; Shitaka Y; Ni K; Matsuoka N
    J Neurochem; 2013 May; 125(3):465-72. PubMed ID: 23240999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
    Levites Y; Das P; Price RW; Rochette MJ; Kostura LA; McGowan EM; Murphy MP; Golde TE
    J Clin Invest; 2006 Jan; 116(1):193-201. PubMed ID: 16341263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.
    Levites Y; Smithson LA; Price RW; Dakin RS; Yuan B; Sierks MR; Kim J; McGowan E; Reed DK; Rosenberry TL; Das P; Golde TE
    FASEB J; 2006 Dec; 20(14):2576-8. PubMed ID: 17068112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model.
    Nojima J; Maeda A; Aoki S; Suo S; Yanagihara D; Watanabe Y; Yoshida T; Ishiura S
    Vaccine; 2011 Aug; 29(37):6252-8. PubMed ID: 21726591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
    Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
    Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.
    Chauhan NB; Siegel GJ
    J Neurosci Res; 2003 Oct; 74(1):142-7. PubMed ID: 13130516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.
    Lord A; Gumucio A; Englund H; Sehlin D; Sundquist VS; Söderberg L; Möller C; Gellerfors P; Lannfelt L; Pettersson FE; Nilsson LN
    Neurobiol Dis; 2009 Dec; 36(3):425-34. PubMed ID: 19703562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
    Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
    Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
    Chauhan NB; Siegel GJ
    Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi.
    Xia W; Zhang J; Ostaszewski BL; Kimberly WT; Seubert P; Koo EH; Shen J; Selkoe DJ
    Biochemistry; 1998 Nov; 37(47):16465-71. PubMed ID: 9843412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
    Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
    Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo.
    Mohajeri MH; Gaugler MN; Martinez J; Tracy J; Li H; Crameri A; Kuehnle K; Wollmer MA; Nitsch RM
    Neurodegener Dis; 2004; 1(4-5):160-7. PubMed ID: 16908985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin.
    Haugabook SJ; Le T; Yager D; Zenk B; Healy BM; Eckman EA; Prada C; Younkin L; Murphy P; Pinnix I; Onstead L; Sambamurti K; Golde TE; Dickson D; Younkin SG; Eckman CB
    FASEB J; 2001 Jan; 15(1):16-18. PubMed ID: 11099491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.